<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277507</url>
  </required_header>
  <id_info>
    <org_study_id>TP900</org_study_id>
    <nct_id>NCT04277507</nct_id>
  </id_info>
  <brief_title>Study of the AERin Medical Vivaer® ARC Stylus for Nasal AirWAY Obstruction</brief_title>
  <acronym>AERWAY</acronym>
  <official_title>A Prospective, Multicenter Study of the AERin Medical Vivaer® ARC Stylus for Nasal AirWAY Obstruction (AERWAY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerin Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerin Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-market study to continue to evaluate the effectiveness of the Vivaer® ARC Stylus for
      nasal airway obstruction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, Multicenter, Non-randomized Study of the Aerin Medical Vivaer® ARC Stylus for
      Nasal Airway Obstruction to continue to evaluate the effectiveness of the Vivaer® ARC Stylus
      for treating the nasal valve area to improve symptoms in those diagnosed with nasal airway
      obstruction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Nasal Obstructive Symptom Evaluation (NOSE) Scores</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months and 24 months post study procedure</time_frame>
    <description>Mean change in NOSE score from Baseline to 24 months post study procedure. Scores may range from the best score of 0, meaning no nasal obstructive symptoms to the worst score of 100, meaning severe nasal obstructive symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in symptoms as documented by the subject in the Quality of Life (QOL) Questionnaire.</measure>
    <time_frame>3 months, 6 months, 12 months and 24 months post study procedure</time_frame>
    <description>Subject self reported study-specific Quality of Life (QOL) Questionnaire - The QOL questionnaire will be used to gain better understanding of the impact of nasal obstruction on the subject's daily activities, feelings, symptoms and medication use. Symptoms will be recorded on a scale of 0, No problem to 5, Problem as bad as it could be. A satisfaction with outcome of Vivaer treatment will be asked in one question on a scale where 1=symptoms have no effect on daily activity to 10=symptoms completely effect daily activity. The QOL will be completed by the subject at 3 months, 6 months, 12 months and 24 months post study procedure.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Subject-reported Visual Analog Scale (VAS) Pain scores in relation to the area treated by the study procedure</measure>
    <time_frame>3 months post study procedure</time_frame>
    <description>Visual Analog Scale (VAS) Pain scores will be evaluated at 3 months post study procedure. VAS scores range from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject reported medication use for nasal obstruction symptoms</measure>
    <time_frame>3 months, 6 months, 12 months and 24 months post study procedure</time_frame>
    <description>Evaluate change in medication used for nasal obstruction symptoms from Baseline to follow up timepoints post study procedure of 3 months, 6 months, 12 months and 24 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject reported type and frequency of adverse events</measure>
    <time_frame>3 months, 6 months, 12 months and 24 months post study procedure</time_frame>
    <description>Evaluate profile by characterizing the type and frequency of adverse events reported at or following the study procedure an throughout the follow up period</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Nasal Obstruction</condition>
  <arm_group>
    <arm_group_label>Vivaer Stylus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivaer Stylus</intervention_name>
    <description>Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area</description>
    <arm_group_label>Vivaer Stylus</arm_group_label>
    <other_name>Aerin Medical Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older

          2. Willing and able to provide informed consent

          3. Willing and able to comply with the study protocol

          4. Seeking treatment for nasal obstruction

          5. NOSE score of ≥ 60 at Baseline

          6. Nasal valve is a primary or significant contributor to the subject's nasal obstruction
             as determined by the study investigator (based on clinical presentation, physical
             examination, nasal endoscopy, etc.) and the subject has a positive response to any of
             the following temporary measures (based on patient history or office exam):

               -  Use of external nasal dilator strips (e.g., Breathe Right Strips)

               -  Q-Tip test (manual intranasal lateralization)

               -  Use of nasal stents

               -  Cottle Maneuver (manual lateral retraction of the cheek)

        Exclusion Criteria:

          1. Prior surgical treatment of the nasal valve

          2. Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal
             procedures within the past three (3) months

          3. Anatomy that requires an adjunctive surgical nasal procedure on the same day or 3
             months after the Vivaer procedure

          4. Medical conditions which in the opinion of the treating physician would predispose the
             subject to poor wound healing or increased surgical risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anais Laborde</last_name>
    <phone>650-518-9624</phone>
    <email>alaborde@aerinmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Winters</last_name>
    <phone>408-506-1866</phone>
    <email>wwinters@aerinmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alabama Nasal and Sinus Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Hagerty</last_name>
      <phone>205-209-4130</phone>
      <email>bhagerty@alabamaallergy.com</email>
    </contact>
    <investigator>
      <last_name>Michael Sillers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristopher Lay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Desert ENT Specialists</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85395</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Chang, PA</last_name>
      <phone>623-512-4199</phone>
      <email>ryan.chang@azdesertent.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Charous, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacramento ENT</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Khalatyan</last_name>
      <phone>916-531-2788</phone>
      <email>rkhalatyan@davinciresearch.net</email>
    </contact>
    <contact_backup>
      <last_name>Kindra Root</last_name>
      <phone>916-531-1380</phone>
      <email>kroot@davinciresearch.net</email>
    </contact_backup>
    <investigator>
      <last_name>Randall Ow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Carlton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tim Fife, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT Associates of South Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Fonseca, RN</last_name>
      <phone>561-939-0175</phone>
      <email>pfonseca@entsf.com</email>
    </contact>
    <investigator>
      <last_name>Nathan Nachlas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT Associates of South Florida</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Elliott</last_name>
      <phone>954-476-0400</phone>
      <email>jelliott@entaaf.com</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Dwyer</last_name>
      <phone>954-476-0400</phone>
      <email>ldwyer@entaaf.com</email>
    </contact_backup>
    <investigator>
      <last_name>Curtis Johnson, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Rosenthal, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Nasal and Sinus Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Pritikin</last_name>
      <phone>312-372-9355</phone>
      <email>becky@chicagonasal.com</email>
    </contact>
    <investigator>
      <last_name>Jordan Pritikin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baton Rouge General / Sinus and Nasal Specialists of Louisiana</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Zito</last_name>
      <phone>225-819-1181</phone>
      <email>bzito@sinusandnasalspecialists.com</email>
    </contact>
    <investigator>
      <last_name>Henry Barham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Hall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Orleans Sinus Center / Tandem Clinical Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Neill</last_name>
      <phone>504-934-8424</phone>
      <email>jneill@tandemclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Adil Fatakia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocare Aroesty ENT Associates</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <zip>07856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Aroesty, MD, FACS, PC</last_name>
      <email>aroestyj@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Aroesty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston ENT and Allergy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Mezta, 0</last_name>
      <phone>281-649-7574</phone>
      <email>emezta@houstonent.com</email>
    </contact>
    <investigator>
      <last_name>Brian Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital / Houston Methodist ENT Specialists</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raquel Bunge</last_name>
      <phone>713-441-3912</phone>
      <email>rrbunge2@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Mas Takashima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Brissett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Mohyuddin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Physicians Otorhinolaryngology - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sorour Ahmadi</last_name>
      <email>sorour.ahmadi@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>William Yao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT Associates of Texas</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisha Neal</last_name>
      <phone>682-718-1778</phone>
      <email>kneal@berksonmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Marshall</last_name>
      <phone>682-718-1778</phone>
      <email>tmarshall@berksonmedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dale Ehmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chad McDuffie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasal valve</keyword>
  <keyword>Nasal airway obstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Airway Obstruction</mesh_term>
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

